Many IDEXX Laboratories, Inc.(IDXX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. IDEXX Laboratories was Downgraded by Feltl & Co. to Sell on Feb 3, 2017.
Company has reported several Insider transactions to the SEC, on Feb 9, 2017, Brian P Mckeon (Executive VP & CFO) sold 9,924 shares at 141.90 per share price.On Feb 9, 2017, Jonathan W Ayers (Chairman, President & CEO) sold 36,250 shares at 141.87 per share price.On Feb 9, 2017, Daniel M Junius (director) sold 3,000 shares at 141.76 per share price.
IDEXX Laboratories Last issued its quarterly earnings results on Feb 2, 2017. The company reported $0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.07. Analyst had a consensus of $0.51. The company had revenue of $443.00 million for the quarter, compared to analysts expectations of $436.07 million. The companys revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 EPS.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2.5 by 8 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 4 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.
IDEXX Laboratories, Inc. (NASDAQ:IDXX): 4 analysts have set the short term price target of IDEXX Laboratories, Inc. (NASDAQ:IDXX) at $125.13. The standard deviation of short term price target has been estimated at $26.21, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 150 and $98 respectively.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) witnessed a decline in the market cap on Tuesday as its shares dropped 0.07% or 0.1 points. After the session commenced at $141.11, the stock reached the higher end at $142 while it hit a low of $140.63. With the volume soaring to 682,783 shares, the last trade was called at $141.6. The company has a 52-week high of $143.47. The company has a market cap of $12,696 million and there are 89,658,209 shares in outstanding. The 52-week low of the share price is $67.85.
IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection, and information products to the animal health industry as well as quality assurance products and services to the food and water industries.